Advances in Multiple Myeloma: Insights from Experts

C. Ola Landgren, MD, recaps a recent panel discussion of the rapidly changing treatment landscape in multiple myeloma, and prospects for future development.

A panel of experts present a profile of a patient with newly diagnosed multiple myeloma (NDMM) and offer their initial thoughts.

An overview of triplet and quadruplet induction regimens used for the treatment of patients with transplant-eligible newly diagnosed multiple myeloma.

Experts on multiple myeloma (MM) discuss factors that determine transplant eligibility for patients who are newly diagnosed.

An expert panel discusses maintenance therapy for patients with MM and offers insights on how induction therapy impacts treatment options.

Myeloma experts present the case of a 74-year-old with transplant-ineligible newly diagnosed MM and offer their initial impressions.

Insights gleaned from the MAIA trial, which researched daratumumab, lenalidomide, and dexamethasone in patients with newly diagnosed MM.

Clinical insights on treatment duration and the decision to place patients with newly diagnosed MM on maintenance therapy.

Experts present the case of a 58-year-old patient with IgG kappa multiple myeloma and offer their initial impressions.

Experts on multiple myeloma discuss approaches to laboratory workup and patient monitoring at the time of relapse.

An overview of multiple myeloma treatment options in the frontline and relapsed settings.

An expert panel discusses bispecific antibodies and their mechanisms of action in the treatment of relapsed/refractory multiple myeloma.

Experts on multiple myeloma discuss the management of adverse effects from bispecific antibodies.

An expert panel compares bispecific antibodies with CAR T-cell therapy and discusses treatment sequencing.

A panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.